Clinical trials: Phobias
Generalized Anxiety Disorder (GAD), Anxiety, Separation
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.
- Conditions
- Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
- Trial name
- NCT01470469
- Testing
- SPD503 (extended-release Guanfacine hydrochloride)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Shire
Social Phobia
Pilot Study: VR Mind and VR Mind+ Intervention
The aim of the pilot study is feasibility, usability and safety assessment of VR Mind intervention. In particular the subject of assessment will be: the length of the laboratory session utilizing virtual reality exposure…
- Trial name
- NCT03647605
- Testing
- VR Mind
- Where
- Poland
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Tomorrow Sp. z o.o.
Phobic Disorders
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
The purpose of this study is to investigate the efficacy of JNJ-42165279 during 12 weeks of treatment in participants with Social Anxiety Disorder (SAD).
- Trial name
- NCT02432703
- Testing
- JNJ-42165279
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 150 people
- Sponsor
- Janssen Research & Development, LLC
Needle Phobia, Phobic Disorders
Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias
An arteriovenous fistula or graft access (AVF/AVG) for dialysis is often considered a superior option for delivery of dialysis, but requires needles to be inserted.
- Trial name
- NCT01623583
- Testing
- Enhanced Needle Phobia Intervention, Standard Needle Phobia Intervention
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Davita Clinical Research
Social Anxiety Disorder
Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder
To determine the anxiolytic efficacy, safety, and tolerability of a flexible-dose of venlafaxine extended release (ER) administered for 16 weeks in the treatment of children and adolescent outpatients with social anxiety disorder…
- Trial name
- NCT00238719
- Testing
- Venlafaxine ER
- Volunteers
- 293 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Social Anxiety Disorder
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
This study evaluates the safety and tolerability of PH94B with repeated dosing over a period of up to 12 months. Participating subjects will use PH94B up to 4 times a day when they encounter anxiety-provoking situations in daily…
- Trial name
- NCT05030350
- Testing
- PH94B
- Where
- 3 sites in United States
- Volunteers
- 481 people
- Sponsor
- VistaGen Therapeutics, Inc.
Social Anxiety Disorder
Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
A phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of CBD and a matching placebo for the treatment of…
- Trial name
- NCT05600114
- Testing
- Cannabidiol oral solution
- Where
- 17 sites in United States
- Volunteers
- 239 people
- Sponsor
- EmpowerPharm Inc.
Post-traumatic Stress Disorder (PTSD)
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
- Trial name
- NCT05189977
- Testing
- Propranolol, Prazosin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Claustrophobia, Complication of Diagnostic Procedure
Comfort Talk and Economic Outcomes in MRI
Annually, an estimated 700,000 patients do not complete their scheduled MRI scans because of claustrophobia or inability to hold still.
- Trial name
- ComfortTalk® (NCT02427737)
- Testing
- Comfort Talk® Training
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Hypnalgesics, LLC
Social Phobia
Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)
The study is designed to evaluate the safety and efficacy of paroxetine on the long-term use in Japanese Social Anxiety Disorder (SAD) subjects.
- Trial name
- NCT01376271
- Testing
- Paroxetine
- Volunteers
- 600 people
- Sponsor
- GlaxoSmithKline
Social Anxiety Disorder
Efficacy of Quetiapine in Generalised Social Anxiety Disorder
This trial will explore the efficacy of quetiapine in Social Anxiety Disorder, generalized type. The following elements of response will be tested: number of responders to treatment, time to response, effect size as measured with…
- Trial name
- NCT00302770
- Testing
- quetiapine
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Anxiety, Obsessive-Compulsive Disorder
Virtual Reality System for Anxiety and OCD
Cognitive Behavioral Therapy with fear provoking exposures is the most effective therapy for anxiety disorders. The investigators aim to enhance this therapy with the use of virtual reality exposures.
- Trial name
- NCT03636022
- Testing
- VR System, Control
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Minnesota HealthSolutions
Social Anxiety Disorder
fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder
Evidence suggests the use of neuroimaging to detect therapeutic effects of anxiolytic treatment when appropriate cognitive-emotional tasks are use to activate the emotional brain neurocircuitry believed to be involved in the core…
- Trial name
- NCT00332046
- Testing
- GW679769
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- GlaxoSmithKline
Social Phobia
Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder
The purpose of this study is to look at the safety and effectiveness of an investigational drug (AV608) when used in subjects who have Social Anxiety Disorder.
- Trial name
- NCT00294346
- Testing
- AV608
- Where
- 15 sites in United States
- Volunteers
- 180 people
- Sponsor
- Avera Pharmaceuticals
Social Anxiety Disorder
Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)
This is a Phase 1b/2a clinical trial to evaluate the safety, tolerability, and efficacy of RLS103 (cannabidiol [CBD] inhaled dry powder) to relieve the anxiety induced by a public speaking challenge in adults with social anxiety…
- Trial name
- NCT05429788
- Testing
- Low dose RLS103, High dose RLS103
- Where
- 3 sites in United States
- Sponsor
- Receptor Life Sciences
Social Phobia
A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder
To compare by neuroimaging techniques the way Social Anxiety patients respond to public speaking before and after a drug administration
- Trial name
- NCT00470483
- Testing
- Paroxetine treatment during 8 weeks
- Where
- Spain
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Social Anxiety Disorder
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
This U.S. multicenter, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the efficacy, safety, and tolerability of a repeat intranasal (i.n.) dose of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to…
- Trial name
- NCT06809179
- Testing
- Fasedienol Nasal Spray - Fasedienol Nasal Spray
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- VistaGen Therapeutics, Inc.
Social Anxiety Disorder
CHI-902 for Treatment of Social Anxiety Disorder
No substantial clinical trials of Cannabidiol (CBD) in Social Anxiety Disorder (SAD) have yet been conducted. This randomized doubleblind, placebo-controlled trial of CBD in adults with SAD will evaluate the efficacy…
- Trial name
- NCT04086342
- Testing
- CHI-902
- Where
- 2 sites in Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Canopy Growth Corporation
Social Anxiety Disorder (SAD)
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in…
- Trial name
- PALISADE-4 (NCT06615557)
- Testing
- Fasedienol Nasal Spray
- Where
- 26 sites in United States
- Volunteers
- 238 people
- Sponsor
- VistaGen Therapeutics, Inc.
Depressive Disorder and Anxiety Disorders
PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients
This six-arm study is being conducted to measure the effect of a combination of paroxetine and vestipitant on the arousal induced by public speaking in Seasonal Effective Disorder (SAD) patients, using functional brain imaging…
- Trial name
- NCT00343707
- Testing
- vestipitant, paroxetine
- Where
- Sweden
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline